Exo-PD-L1 levels were significantly higher in NSCLC patients compared to healthy donors, especially in those with advanced tumor features, while sPD-L1 levels showed no significant difference between the two groups (58). This evidence concerns the gene CD274 and non-small cell lung carcinoma.